Placeholder Banner

BIO as Amicus Curiae supporting en banc reconsideration in Prolitec, Inc. v. ScentAir Technologies, Inc. (US Court of Appeals for the Federal Circuit)

February 16, 2016

BIO as Amicus Curiae supporting en banc reconsideration in Prolitec, Inc. v. ScentAir Technologies, Inc. (US Court of Appeals for the Federal Circuit)

 
STATEMENT OF INTEREST OF AMICUS CURIAE
The Biotechnology Innovation Organization (“BIO”) (formerly: Biotechnology Industry Organization) is the principal trade association representing the biotechnology industry domestically and abroad. BIO’s members depend on robust patent rights and a fair system for adjudicating their validity, including the ability to amend claims in inter partes review (IPR). Accordingly, the question of who has the burden of proof, and what must be proved, before a claim amendment can be entered in IPR is of great importance to BIO’s membership.
Discover More
The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge the Federal Trade Commission (FTC) lawsuit to block the acquisition of Horizon by Amgen. The amicus brief was filed in the U.S. District Court, Northern…
BIO has filed an amicus brief in U.S. ex rel. Scutte v. SuperValu Inc., which addresses the issue of the intent requirement under the False Claims Act (FCA). Specifically, BIO urges the Court to uphold the view that a firm does not…
The Biotechnology Innovation Organization (BIO) today signed onto an amicus brief to challenge a District Court’s unprecedented ruling (related to a single drug known as mifepristone) that would create regulatory barriers and potentially upend FDA’s…